



产品介绍 评论(0)
物种
Mouse抗原名称
CD155/PVR分子别名
FLJ25946, PVS, TAGE4, HVED, NECL5Accession
Q8K094表达序列
Asp29-Leu348, with C-terminal Human IgG1 Fc表达宿主
HEK293分子量
75-95kDa纯度
>95% by SDS-PAGE内毒素含量
<0.1EU/μg标记
Unconjugated标签
Human Fc性状
Lyophilized Powder缓冲体系
PBS, pH7.4溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1. Liu Lu ,Wang Ying ,Geng Chen,Wang Aihong ,Han Sai ,You Xuewu ,Sun Yu ,Zhang Junhua ,Lu Wei ,Zhang Youzhong. CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-kappa B Pathways. [J] FRONTIERS IN ONCOLOGY.2021-07-05(11).
CD155 is a member of the immunoglobulin superfamily also known as the human receptor for poliovirus (PVR). The full length (or PVR alpha isoform) is synthesized as a 417 amino acid (aa) precursor that contains a 20aa signal sequence, a 323aa extracellular region, a 24aa TM segment and a 50aa cytoplasmic tail. It has been demonstrated that CD155 can be recognized and bond by DNAM-1 and CD96 which promote the adhesion, migration and NK-cell killing, and thus efficiently prime cell-mediated tumor-specific immunity. CD155 is expressed at high levels in several human malignancies and seems to have pro tumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic viro therapy.
电泳
1μg (R: reducing conditions, N: non-reducing conditions).
ELISA
Immobilized TIGIT His Tag, Mouse (Cat. No. UA010084) at 2.0μg/mL (100μL/well) can bind CD155/PVR Fc Chimera, Mouse (Cat. No. UA010572) with EC50 of 0.13-0.19μg/mL .
分子互作
Protein A Chip captured CD155/PVR Fc Chimera, Mouse (Cat. No. UA010572), can bind . TIGIT His Tag, Mouse (Cat. No. UA010084) with an affinity constant of 1.46μM as determined in SPR assay.







评论(0)